Triflusal, > = 98 %(HPLC) ,POUDRE

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Features and Benefits

This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle